VectivBio

Acquired

Ironwood Pharmaceuticals | Leaders in GI Health Innovation

Basel, Switzerland · Founded 2019 · $145.0M raised

Headquarters
Basel
Employees
11–50
Founded
2019
Business Model
B2B
Total Funding
$145.0M
Last Round
$110.0M Venture RoundJan 2023
Rounds
3
Acquired by
Ironwood PharmaceuticalsMay 2023

About

VectivBio was a clinical-stage biotechnology company headquartered in Basel, Switzerland, focused on the discovery and development of treatments for severe rare gastrointestinal diseases. Its lead candidate, apraglutide, is an investigational GLP-2 analog designed for short bowel syndrome with intestinal failure. VectivBio listed on NASDAQ in April 2021 and was acquired by Ironwood Pharmaceuticals in June 2023 for approximately $1 billion.

Summary

VectivBio is a Biotech company based in Basel, Switzerland, founded in 2019. It has raised $145.0M in total across 3 rounds, most recently a $110.0M Venture Round round in Jan 2023. Investors include Ironwood Pharmaceuticals, CTI Life Sciences Fund and Novo Holdings A/S.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionMay 2023
$1.0B

Sign up to see all 4 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

VectivBio on Indexed.vc
<a href="https://indexed.vc/companies/vectivbio"><img src="https://indexed.vc/api/badge/company/vectivbio" alt="VectivBio on Indexed.vc" width="260" height="76" /></a>